Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Research at Kyorin leads to potent, nontoxic and water-soluble camptothecin derivative

Sep. 17, 1999

German company obtains renal cell carcinoma MAb license from Centocor

Sep. 16, 1999

UroCor and Mallinckrodt enter marketing agreement for brachytherapy implants

Sep. 16, 1999

Pharmacological characteristics of PK inhibitor CGP-41251 explored

Sep. 16, 1999

New phase I/II data on AE-941/Neovastat in lung cancer presented at ECCO 10

Sep. 15, 1999

New antitumor illudin analogues synthesized at U. of California

Sep. 15, 1999

Depsipeptide tested in vitro for B-cell CLL inhibition

Sep. 15, 1999

Cell Pathways continues to investigate apoptosis-promoting compounds for neoplastic diseases

Sep. 14, 1999

MS-275: new benzamide inhibitor of histone deacetylase selected as development candidate

Sep. 14, 1999

Phase II trial expanded for Aronex's renal cell carcinoma product

Sep. 13, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...